| Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition L Corey, PB Gilbert, M Juraska, DC Montefiori, L Morris, ST Karuna, ... New England Journal of Medicine 384 (11), 1003-1014, 2021 | 319 | 2021 |
| Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120–MF59 in adults GE Gray, LG Bekker, F Laher, M Malahleha, M Allen, Z Moodie, ... New England Journal of Medicine 384 (12), 1089-1100, 2021 | 180 | 2021 |
| Anemia among HIV-infected patients initiating antiretroviral therapy in South Africa: improvement in hemoglobin regardless of degree of immunosuppression and the initiating ART … S Takuva, M Maskew, AT Brennan, I Sanne, AP MacPhail, MP Fox Journal of tropical medicine 2013, 2013 | 73 | 2013 |
| Effectiveness of the Ad26. COV2. S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study LG Bekker, N Garrett, A Goga, L Fairall, T Reddy, N Yende-Zuma, ... The Lancet 399 (10330), 1141-1153, 2022 | 59 | 2022 |
| Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort S Takuva, M Maskew, AT Brennan, L Long, I Sanne, MP Fox African Journal of Reproduction and Gynaecological Endoscopy 17 (1), 2014 | 58 | 2014 |
| Thromboembolic events in the South African Ad26. COV2. S vaccine study S Takuva, A Takalani, N Garrett, A Goga, J Peter, V Louw, J Opie, ... New England Journal of Medicine 385 (6), 570-571, 2021 | 57 | 2021 |
| The continuum of HIV care in South Africa: implications for achieving the second and third UNAIDS 90-90-90 targets S Takuva, AE Brown, Y Pillay, V Delpech, AJ Puren Aids 31 (4), 545-552, 2017 | 53 | 2017 |
| Efficacy, safety, and immunogenicity of a booster regimen of Ad26. COV2. S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled … K Hardt, A Vandebosch, J Sadoff, M Le Gars, C Truyers, D Lowson, ... The Lancet Infectious Diseases 22 (12), 1703-1715, 2022 | 47 | 2022 |
| Rates of virological suppression and drug resistance in adult HIV-1-positive patients attending primary healthcare facilities in KwaZulu-Natal, South Africa GM Hunt, EK Dokubo, S Takuva, T de Oliveira, J Ledwaba, N Dube, ... Journal of Antimicrobial Chemotherapy 72 (11), 3141-3148, 2017 | 41 | 2017 |
| Prevalence of peripheral neuropathy in antiretroviral therapy naïve HIV-positive patients and the impact on treatment outcomes—a retrospective study from a large urban cohort … D Evans, S Takuva, M Rassool, C Firnhaber, M Maskew Journal of neurovirology 18, 162-171, 2012 | 32 | 2012 |
| Durability of first line antiretroviral therapy: reasons and predictive factors for modifications in a Swaziland cohort SG Takuva, G Louwagie, K Zuma, V Okello OMICS Publishing, 2012 | 31 | 2012 |
| CD4 count recovery and associated factors among individuals enrolled in the South African antiretroviral therapy programme: An analysis of national laboratory based data T Kufa, Z Shubber, W MacLeod, S Takuva, S Carmona, J Bor, M Gorgens, ... PloS one 14 (5), e0217742, 2019 | 28 | 2019 |
| Etiology and antimicrobial susceptibility of pathogens responsible for urethral discharge among men in Harare, Zimbabwe S Takuva, O Mugurungi, J Mutsvangwa, A Machiha, AC Mupambo, ... Sexually transmitted diseases 41 (12), 713-717, 2014 | 28 | 2014 |
| An association between decreasing incidence of invasive non-typhoidal salmonellosis and increased use of antiretroviral therapy, Gauteng Province, South Africa, 2003–2013 KH Keddy, S Takuva, A Musekiwa, AJ Puren, A Sooka, A Karstaedt, ... PloS one 12 (3), e0173091, 2017 | 25 | 2017 |
| Risk factors for discordant immune response among HIV-infected patients initiating antiretroviral therapy: A retrospective cohort study BP Muzah, S Takuva, M Maskew, S Delany-Moretlwe Southern African Journal of HIV Medicine 13 (4), 168-172, 2012 | 24 | 2012 |
| A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection in women in sub-Saharan Africa … NM Mgodi, S Takuva, S Edupuganti, S Karuna, P Andrew, E Lazarus, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 87 (1), 680-687, 2021 | 23 | 2021 |
| Cameroon Public Expenditure Review: Aligning Public Expenditures with the Goals of Vision 2035 World Bank World Bank, 2018 | 21* | 2018 |
| Incidence and predictors of recovery from anaemia within an HIV-infected South African Cohort, 2004-2010 Z Ndlovu, T Chirwa, S Takuva Pan African Medical Journal 19 (1), 2014 | 18 | 2014 |
| HIV-associated lipodystrophy in South Africa: the impact on the patient and the impact on the plastic surgeon RJ Zinn, C Serrurier, S Takuva, I Sanne, CN Menezes Journal of Plastic, Reconstructive & Aesthetic Surgery 66 (6), 839-844, 2013 | 15 | 2013 |
| Cost-effectiveness analysis of flucytosine as induction therapy in the treatment of cryptococcal meningitis in HIV-infected adults in South Africa J Miot, T Leong, S Takuva, A Parrish, H Dawood BMC Health Services Research 21, 1-11, 2021 | 14 | 2021 |
